My Cart
You have no items in your shopping cart.
Background
The human CACNA1C gene encodes the pore-forming subunit of voltage-gated L-type Ca2+ channels. Co-expression with the β2 and α2δ1 auxiliary subunits recapitulates function in heterologous expression (CHO cells). Cav1.2 channels are therapeutic targets for cardiac arrhythmia and hypertension. Gabapentin (Neurontin) has been shown to bind to the α2δ subunit of the calcium channel (Gee et al., 1996)
| General Info | |
| Synonyms | L-type calcium channel |
|---|---|
| Product Description | Human Cav1.2/β2/α2δ1 Calcium Channel membrane preparation derived from stable, replicating cell line. |
| Target Type | Ion Channel |
| Product Type | membrane |
| Sub-Type | Cav1.2/β2/α2δ1 |
| Class | Voltage-gated calcium channel |
| Therapeutic Area | cancer, cardiac, vascular |
| Related Services | Membrane Preparation |
| Gene Name | CACNA1C/CACNB2/CACNA2D1 |
| Validated Assay/Platform | binding |
| References | Catterall WA et al. 2005. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 57:411-25 Gee, N.S. et al. 1996 The Novel anticonvulsant drug, gabapentin (Ne |
| Membrane Info | |
| Host cell | CHO-K1 |
| Recommended Assay Conditions | Refer to product specification sheet for details |
| Storage and Packaging | |
| Packaging | 0.4 mL of membranes at a protein concentration of 2.5 mg/mL |
| Storage Recommendation | -80°C; Avoid repeated freeze-thawing of this product. |
| Quantity | 400 µL/vial |
| Media | |
| Specification Sheet |  Download PDF Document |
